5-HO-DPT
Pharmaceutical compound
From Wikipedia, the free encyclopedia
5-HO-DPT, also known as 5-hydroxy-N,N-dipropyltryptamine, as well as N,N-dipropylserotonin (DiPS or NDPS), is a serotonin receptor modulator of the tryptamine and 5-hydroxytryptamine families.[1] It is the N,N-dipropyl derivative of serotonin (5-hydroxytryptamine; 5-HT).[1]
- None
| |
 | |
| Clinical data | |
|---|---|
| Other names | 5-Hydroxy-N,N-dipropyltryptamine; N,N-Dipropylserotonin; N,N-Di-n-propylserotonin; DiPS; NDPS |
| Drug class | Serotonin receptor modulator |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C16H24N2O |
| Molar mass | 260.381 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pharmacology
Pharmacodynamics
The drug shows affinity for the serotonin 5-HT1A receptor (Ki = 7.1 nM), the serotonin 5-HT1B receptor (Ki = 4,300 nM), and the serotonin 5-HT2 receptor (Ki = 1.0–450 nM).[1] 5-HO-DPT was not tested itself, but its O-methyl ether 5-MeO-DPT fully substituted for the psychedelic drug DOM in rodent drug discrimination tests and partially substituted for 8-OH-DPAT in these tests followed by behavioral disruption at higher doses.[1]
5-Hydroxytryptamines like bufotenin (5-HO-DMT) are known to be hydrophilic and peripherally selective, in turn resulting in difficulty crossing the blood–brain barrier and exerting central effects.[1] However, 5-HO-DPT is notable in having much greater lipophilicity in comparison to bufotenin owing to its propyl groups (predicted log P = 3.0 and 1.2, respectively).[2][3]
Chemistry
History
5-HO-DPT was first described in the scientific literature by Richard Glennon and colleagues by 1988.[1]